236 related articles for article (PubMed ID: 18231644)
1. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.
Towns K; Bedard PL; Verma S
Curr Oncol; 2008 Jan; 15(Suppl 1):S16-29. PubMed ID: 18231644
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Cardiac effects of adjuvant therapy for early breast cancer.
Theodoulou M; Seidman AD
Semin Oncol; 2003 Dec; 30(6):730-9. PubMed ID: 14663774
[TBL] [Abstract][Full Text] [Related]
4. Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer.
O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S11-21. PubMed ID: 18282366
[TBL] [Abstract][Full Text] [Related]
5. Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.
Du F; Yuan P; Zhu W; Wang J; Ma F; Fan Y; Xu B
Med Oncol; 2014 Dec; 31(12):340. PubMed ID: 25416049
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for breast cancer.
Hennessy BT; Pusztai L
Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
[TBL] [Abstract][Full Text] [Related]
7. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
[TBL] [Abstract][Full Text] [Related]
8. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.
Bird BR; Swain SM
Clin Cancer Res; 2008 Jan; 14(1):14-24. PubMed ID: 18172247
[TBL] [Abstract][Full Text] [Related]
9. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant chemotherapy of early stage breast cancer].
Boér K
Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
[TBL] [Abstract][Full Text] [Related]
11. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Perez EA
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
[TBL] [Abstract][Full Text] [Related]
12. [Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer].
Tanz R; Magne N; Annede P; Mery B; Jacob J; Bauduceau O; Trone JC; Guichard JB; Meillan N; Kirova Y; Vedrine L; Chargari C
Bull Cancer; 2014; 101(7-8):730-40. PubMed ID: 25091656
[TBL] [Abstract][Full Text] [Related]
13. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Ewer MS; O'Shaughnessy JA
Clin Breast Cancer; 2007 Jun; 7(8):600-7. PubMed ID: 17592672
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines.
Crozier JA; Swaika A; Moreno-Aspitia A
World J Clin Oncol; 2014 Aug; 5(3):529-38. PubMed ID: 25114866
[TBL] [Abstract][Full Text] [Related]
15. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
16. Controversies in breast cancer: adjuvant and neoadjuvant therapy.
Montemurro F; Redana S; Valabrega G; Aglietta M
Expert Opin Pharmacother; 2005 Jun; 6(7):1055-72. PubMed ID: 15957962
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
18. Use of non-anthracycline regimens in early stage breast cancer in Australia.
de Boer RH; Chan A; Tran B; Wilcken N
Asia Pac J Clin Oncol; 2011 Mar; 7(1):4-10. PubMed ID: 21332644
[TBL] [Abstract][Full Text] [Related]
19. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
Burstein HJ; Harris LN; Gelman R; Lester SC; Nunes RA; Kaelin CM; Parker LM; Ellisen LW; Kuter I; Gadd MA; Christian RL; Kennedy PR; Borges VF; Bunnell CA; Younger J; Smith BL; Winer EP
J Clin Oncol; 2003 Jan; 21(1):46-53. PubMed ID: 12506169
[TBL] [Abstract][Full Text] [Related]
20. Controversies in the therapy of early stage breast cancer.
Cianfrocca M; Gradishar WJ
Oncologist; 2005; 10(10):766-79. PubMed ID: 16314287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
